← Back to headlines
Novo Nordisk Wins US FDA Approval for Once-Weekly Insulin Awiqli for Type 2 Diabetes
Novo Nordisk has secured US FDA approval for its once-weekly insulin Awiqli, expanding its presence in diabetes care and offering a new treatment option for type 2 diabetes.
27 Mar, 11:09 — 27 Mar, 11:09
Sources
Showing 1 of 2 sources
Coverage Timeline
First report: berlingske · 27 Mar, 07:56|Full coverage: 2 · 3h|Window: 3h
Left-leaningCenterRight-leaning
Related Stories
Experts Recommend 30-Minute Daily Walks from Age 35 for Health Benefits
10m ago
Elderly 'Strong Silvers' Team, Aged 73-86, Maintains Daily Workout Routine
30m ago
Eli Lilly Extends Partnership with Insilico Medicine for AI Drug Discovery
37m ago
QuickCheck Debunks Coconut Water's Efficacy in Dissolving Kidney Stones
41m ago